BioCentury
ARTICLE | Clinical News

Ablynx's ozoralizumab meets RA endpoint

May 18, 2011 1:09 AM UTC

Ablynx N.V. (Euronext:ABLX) said ozoralizumab met the primary endpoint in a Phase II trial to treat rheumatoid arthritis. The anti- tumor necrosis factor (TNF) alpha nanobody significantly improved AC...